HC Wainwright Weighs in on Pelthos Therapeutics Q1 Earnings

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Stock analysts at HC Wainwright reduced their Q1 2026 EPS estimates for Pelthos Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($4.49) for the quarter, down from their previous forecast of ($1.88). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q2 2026 earnings at ($3.48) EPS, Q3 2026 earnings at ($2.29) EPS, Q4 2026 earnings at ($2.60) EPS, FY2026 earnings at ($14.39) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at $10.86 EPS, FY2029 earnings at $15.42 EPS and FY2030 earnings at $18.79 EPS.

Several other brokerages have also recently issued reports on PTHS. Oppenheimer lifted their price target on Pelthos Therapeutics from $60.00 to $62.00 and gave the company an “outperform” rating in a research report on Friday. Piper Sandler assumed coverage on Pelthos Therapeutics in a research note on Friday, February 27th. They set an “overweight” rating and a $48.00 target price for the company. Zacks Research lowered Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, January 30th. Finally, Roth Mkm dropped their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.25.

Pelthos Therapeutics Price Performance

Shares of NYSEAMERICAN:PTHS opened at $22.00 on Monday. The company has a market capitalization of $73.92 million, a PE ratio of -1.06 and a beta of 3.86. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.15 and a current ratio of 2.05. Pelthos Therapeutics has a 12 month low of $9.00 and a 12 month high of $54.29. The business’s 50 day moving average price is $23.25.

Institutional Investors Weigh In On Pelthos Therapeutics

Several large investors have recently modified their holdings of PTHS. Ikarian Capital LLC raised its position in shares of Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after purchasing an additional 193,307 shares during the period. Boothbay Fund Management LLC raised its holdings in Pelthos Therapeutics by 279.8% during the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares during the period. J. Goldman & Co LP purchased a new stake in Pelthos Therapeutics during the fourth quarter valued at about $2,418,000. Cantor Fitzgerald L. P. purchased a new stake in Pelthos Therapeutics during the fourth quarter valued at about $1,085,000. Finally, Diadema Partners LP boosted its holdings in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after buying an additional 14,502 shares during the period. 77.96% of the stock is owned by institutional investors.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).